Rapamycin-Conjugated Stem Cells for Sustained Pulmonary Fibrosis Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic agents for pulmonary fibrosis, such as pirfenidone and nintedanib, only delay fibrosis progression and have stomach-related side effects, lacking a mechanism to reverse or significantly inhibit fibrosis, and there is a need for a more effective treatment.

Innovation Solution

Development of mesenchymal stem cells conjugated with a rapamycin-containing drug carrier, where rapamycin is loaded inside the carrier and coated with polydopamine, enhancing anti-fibrotic factor production without affecting cell viability, and improving drug delivery and release duration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If current therapeutic agents (pirfenidone and nintedanib) are used to treat pulmonary fibrosis, then fibrosis progression is delayed, but they cannot reverse fibrosis and cause stomach-related side effects

Engineering Contradiction:

Improvedelay of fibrosis progressionVSAvoidstomach-related side effects

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The therapeutic approach is segmented into two distinct components: stem cells that migrate to fibrotic tissue and rapamycin delivered via drug carriers that are conjugated to the stem cell surface. This segmentation allows the drug to be delivered directly to the target site through the stem cells, bypassing the gastrointestinal system and avoiding stomach-related side effects while maintaining therapeutic efficacy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Stem cells serve as intermediaries that carry rapamycin-containing drug carriers directly to fibrotic tissue. The stem cells migrate to the target site and release the drug carriers, which then deliver rapamycin to inhibit fibrosis. This intermediary approach enables targeted drug delivery, improving therapeutic effectiveness while avoiding systemic side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If rapamycin is administered to inhibit fibrosis-related factor expression, then anti-fibrotic effect is enhanced, but cell viability may be affected

Engineering Contradiction:

Improveanti-fibrotic effectVSAvoidcell survival rate

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The drug delivery system exhibits local quality by concentrating rapamycin delivery at the fibrotic tissue site through stem cell-mediated targeting. The drug carriers are released specifically where fibrosis is present, providing high local drug concentration for effective anti-fibrotic action while maintaining low systemic drug levels that preserve cell viability elsewhere.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The system changes the parameter of drug concentration distribution by using stem cells to deliver rapamycin locally to fibrotic tissue rather than systemic administration. This creates a localized high concentration gradient that achieves therapeutic effect at the target site while maintaining safe drug levels systemically, thus preserving cell viability.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If stem cells are used alone for pulmonary fibrosis treatment, then cell therapy effect is provided, but sustained drug delivery and enhanced anti-fibrotic factor production are insufficient

Engineering Contradiction:

Improvecell therapy effectVSAvoiddrug delivery duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention merges stem cell therapy with pharmacological treatment by conjugating rapamycin-containing drug carriers to the stem cell surface. This combination allows the stem cells to provide their inherent therapeutic effects while simultaneously delivering rapamycin for sustained inhibition of fibrosis, enhancing both the duration and effectiveness of the treatment.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The drug carriers conjugated to stem cells provide continuous drug delivery as the stem cells migrate and reside in the fibrotic tissue. This ensures sustained release of rapamycin over time, maintaining continuous anti-fibrotic action rather than transient effects from single-dose administration.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The stem cell-drug carrier effectively inhibits fibrosis-related protein expression, enhances survival rate and anti-fibrotic factor secretion, and provides a sustained therapeutic effect for pulmonary fibrosis.

Implementation Method 1

a rapamycin-containing drug carrier coated with polydopamine

Methodology Applied

Scientific EffectAdhesion: Adhesive

Data Source

PatentUS20250345314A1Stem cell conjugated with rapamycin-containing drug carrier and uses thereof

Publication Date: 2025.11.13 KANGSTEM BIOTECH

AI summary

The present disclosure relates to a stem cell conjugated with a rapamycin-containing drug carrier, and more particularly, to uses of the stem cell for treating pulmonary fibrosis and inhibiting fibrosis. According to the present disclosure, it was experimentally confirmed that the stem cell conjugated with the rapamycin-containing drug carrier had an excellent effect of inhibiting the expression of fibrosis-related proteins in pulmonary fibroblasts induced with fibrosis. Therefore, the stem cell conjugated with the rapamycin-containing drug carrier of the present disclosure may be used in various fields of research related to fibrosis and treatment of pulmonary fibrosis.